You are here

Home » Content

Tip 2 diabetes mellitusta oral antidiyabetik tedavi yaklaşımları

Oral antidiabetic treatment approaches in type 2 diabetes mellitus

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2010
DOI: 
doi:10.2399/tahd.10.001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Type 2 diabetes mellitus is a chronic illness characterized with hyperglycemia which is a result of insulin resistance and generally accompanying relative insulin insufficiency, which constitues 80- 90% of all diabetics. It is shown that lowering the glycemic levels of diabetic patients to near normal ranges is effective in preventing or delaying diabetes related complications. There are different oral antidiabetic agents with different mechanisms of actions used in type 2 diabetes mellitus treatment. Updating treatment approaches in type 2 diabetes mellitus is important for having better glycemic control, better quality of life and longevity.
Bookmark/Search this post with
Abstract (Original Language): 
Tip 2 diabetes mellitus insülin direnci ve genellikle eşlik eden röla-tif insülin yetmezliği sonucu hiperglisemi ile karakterize kronik bir hastalık olup, tüm diyabetlilerin yaklaşık % 80-90'ını oluşturmaktadır. Diyabetli hastaların glisemi düzeylerinin normale yakın aralıkta tutulmasının diyabetle ilişkili komplikasyonların gelişiminin engellenmesinde ya da geciktirilmesinde etkili olduğu gösterilmiş¬tir. Tip 2 diyabet tedavisinde kullanılan, farklı mekanizmalarla et¬kilerini gösteren farklı oral antidiyabetik ajanlar bulunmaktadır. Daha iyi glisemik kontrolü sağlamaya, yaşam kalite ve süresini artırmaya yönelik olarak tip 2 diyabet tedavisindeki yaklaşımların güncellenmesi önemlidir.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_14_pp_1-7.pdf
  • 1
1-7
  • Turkish

REFERENCES

References: 

1. Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA, Avery MA. Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem 2008; 15: 61-74.
2. Masharani U, German MS. Pancreatic hormones and diabetes mellitus. Greenspan's Basic and Clinical Endocrinology'de. Ed. Gardner DG, Shoback D. 8. baskı. California, The McGraw Hill Companies, 2007; 661-747.
3. Nathan DM, Buse JB, Davidson MB, ve ark. American Diabetes Association; European Association for Study of Diabetes. Medical man¬agement of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
5. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
6. Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Curr Med Res
Opin 2007; 23: 905-17.
7. Davidson JA, Chan JCN. The role of metformin in polycystic ovary syn¬drome and infertility. Metformin, The Gold Standard A Scientific Handbook'da. Ed. Bailey CJ, Campbell IW, Chan JCN, Davidson JA,
Howlett HCS, Ritz P. Chichester, Wiley, 2007; 223-31.
8. Chyan YJ, Chuang LM. Dipeptidyl peptidase-IV inhibitors: An evolving treatment for type 2 diabetes from the incretin concept. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery 2007; 1: 15-24.
9. Pratley RE. Expanding treatment options for type 2 diabetes: the old and the new. Diabetes Educ 2009; 35 Suppl 1: 4-11.
10. Çorakçı A, Azal Ö, Beyhan Z. Diabetes mellitus'ta oral ajan tedavisi. Diabetes Mellitus 2009'da. Ed. İmamoğlu fi, Özyardımcı Ersoy C. 2. baskı. İstanbul, Deomed Medikal Yayıncılık, 2009; 137-75.
11. Nathan DM, Buse JB, Davidson MB ve ark. Management of hyper-glycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-72.
12. Nathan DM, Buse JB, Davidson MB ve ark. Management of hyper-glycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31: 173-5.
13. Tibaldi J, Rakel RE. Why, when and how to initiate insulin therapy in patients with type 2 diabetes. Int J Clin Pract 2007; 61: 633-44.

Thank you for copying data from http://www.arastirmax.com